Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Growth regulator holds promise for more targeted treatment
July 14th, 2005
Researchers at Yale University School of Medicine have discovered a breast cancer growth regulator, sEGFR, which may be a useful tool in monitoring a patient's responsiveness to treatment with the drug letrozole. Published in a recent issue of Cancer Research, the study focused on how decreased concentrations of sEGFR can indicate the effectiveness of letrozole. In women with postmenopausal breast cancer, estrogen often stimulates tumor growth. Letrozole, which is currently used in breast cancer therapy, stops the local production of estrogen, therefore reducing tumor growth. To monitor the effectiveness of this drug's reduction in tumor...
Source: Women's Health Weekly (2005-07-14)
|
